Phase II Trial of Zanzalintinib (XL-092) in Combination With Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)

Bookmark
Investigational drug late phase More information Active drug More information Moderate burden on patient More information

Trial Details

Sponsor: Anwaar Saeed (other)

Phase: 2

Start date: Dec. 9, 2024

Planned enrollment: 40

Trial ID: NCT06698250
Copy trial ID
More trial details at ClinicalTrials.gov More info

chevron Show Summary from Sponsor

Investigational Drug AI Analysis

chevron Show for: Zanzalintinib (XL092)

HealthScout AI Analysis

Goal: Evaluate whether the multi‑target TKI zanzalintinib (XL‑092) can modulate the HCC tumor microenvironment to enhance antitumor activity when combined with dual immune checkpoint blockade (durvalumab plus a single priming dose of tremelimumab), and to determine the recommended phase 2 dose and antitumor efficacy in unresectable HCC.

Patients: Adults (≥18 years) with unresectable hepatocellular carcinoma who are systemic therapy–naïve in the unresectable setting, ECOG 0–1, adequate organ function, Child-Pugh A (score ≤7), and able to provide baseline tumor tissue (fresh biopsy or qualifying archival). Key exclusions include prior PD‑(L)1, CTLA‑4, or XL‑092 exposure; recent systemic anticancer therapy or radiation; uncontrolled cardiovascular or significant GI comorbidities; active significant bleeding risk, brain metastases not adequately treated, active infections including HBV/HCV/HIV, clinically meaningful ascites or recent hepatic encephalopathy; need for systemic immunosuppression; and QTcF prolongation.

Design: Phase 2, open-label, non-randomized, two-part study with a rolling 6 safety lead-in (approximately 9–12 patients) to establish the RP2D of XL‑092 with durvalumab plus tremelimumab, followed by phase 2 cohorts comparing two sequencing strategies for initiation of XL‑092 versus durvalumab+tremelimumab. Planned enrollment is 40 patients.

Treatments: All patients receive the triplet of zanzalintinib (XL‑092) orally once daily on days 1–28 of 28‑day cycles, durvalumab 1500 mg IV day 1 of each cycle, and a single priming dose of tremelimumab 300 mg IV. Safety lead-in evaluates XL‑092 dose levels (40, 60, 100 mg) using a dose-limiting toxicity window of 84 days to define the RP2D. In phase 2, two schedules are tested: (1) first-cycle XL‑092 with durvalumab+tremelimumab starting cycle 2; or (2) first-cycle durvalumab+tremelimumab with XL‑092 starting cycle 2. Zanzalintinib (XL‑092) is an oral, next-generation multi-kinase inhibitor targeting VEGFR2, MET, and TAM family kinases (TYRO3, AXL, MER), which regulate angiogenesis, tumor growth, and immune suppression. It has a shorter half-life supporting once-daily dosing and is designed with a target profile similar to cabozantinib but with improved pharmacokinetics. Early phase 1 data in heavily pretreated ccRCC showed an objective response rate of about 38% and disease control of 88%, including activity post-cabozantinib, with manageable toxicity profiles dominated by class-typical events (diarrhea, hypertension, asthenia, decreased appetite, proteinuria). Durvalumab is an anti–PD-L1 antibody; tremelimumab is an anti–CTLA-4 antibody given as a single priming dose to augment initial T‑cell activation.

Outcomes: Primary endpoints are the recommended phase 2 dose of XL‑092 with durvalumab plus tremelimumab (per 84‑day DLT window, CTCAE v5.0) and objective response rate by immune‑modified RECIST v1.1. Secondary endpoints include ORR by RECIST v1.1, disease control rate by imRECIST, progression‑free survival (median and 6‑month rate), overall survival (6‑, 12‑, 24‑, and 36‑month rates and median OS), and rate of conversion to resection or transplant.

Burden on patient: Moderate to high. The regimen combines continuous daily oral TKI with recurring IV infusions and requires mandatory baseline tumor tissue, typically necessitating a fresh biopsy if archival tissue is not adequate. Safety lead-in participants face intensive toxicity monitoring during the 84‑day DLT period, with frequent clinic visits, labs, and potential dose adjustments. Subsequent cycles involve monthly infusion visits for durvalumab (with a one-time tremelimumab infusion), routine imaging for response assessments, and standard safety labs; TKI‑class adverse events and immune-related toxicities may prompt additional visits, laboratory checks, and supportive care. Travel burden includes monthly infusion center attendance and possible biopsy-related visits, exceeding standard single‑agent IO schedules in unresectable HCC.

Last updated: Oct 2025

Eligibility More information

chevron Show Criteria

Sites (1)

Sort by distance to:
Clear

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States

[email protected] / 412-623-8364

Status: Recruiting

Back to trials list